Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Why 3SBio Is On Investors' Radar Today

3SBio (SEHK:1530) has caught attention after a stretch of mixed share performance, with a 1 day decline and weaker moves over the past month and past 3 months prompting a closer look at fundamentals.

See our latest analysis for 3SBio.

The 1 day share price return of a 2.82% decline comes on the back of a 30 day share price return of a 17.23% decline and a 90 day share price return of a 31.82% decline, even though the 1 year total shareholder return sits at roughly 2.7x. This suggests long term holders have still seen very strong gains despite recently fading momentum.

If you are reassessing your exposure to healthcare names after this move, it may be a time to look at our screener of healthcare focused AI opportunities through 106 healthcare AI stocks as a way to surface other ideas.

With 3SBio trading below some valuation estimates and recent revenue and net income growth data looking softer, the key question is whether current weakness signals an undervalued healthcare name or a market that already reflects its future growth.

Preferred P/E of 21.9x: Is it justified?

3SBio's P/E of 21.9x sits well below both its peer group and the wider Asian biotechs, which immediately stands out given the recent share price pullback.

P/E compares the current share price to earnings per share, so you are effectively seeing how much investors are paying today for each unit of profit. For a biopharmaceutical group with HK$2,358.6m in net income and high quality earnings, this yardstick helps you judge whether the market is putting a rich or modest tag on those profits.

Here, 3SBio is described as good value on a P/E basis versus its direct peers, with its 21.9x multiple sitting against a peer average of 83.5x. It is also framed as good value versus the broader Asian biotechs industry, where the average is 42x. At the same time, the shares are flagged as expensive relative to an estimated fair P/E of 18.8x. This indicates a level the market could move toward if sentiment cools or earnings expectations reset.

Overall, the comparison suggests the stock trades at a discount to sector and peer valuations, while still carrying a premium to the internally estimated fair P/E that some investors may watch closely over time.

Explore the SWS fair ratio for 3SBio

Result: Price-to-earnings of 21.9x (UNDERVALUED)

However, softer annual revenue and net income growth, along with a 31.82% 90-day share price decline, could signal pressure on the current valuation story.